Table 2.
The relationship between CAMKII expression and the clinicopathological characteristics of lung ADC
| Variable | Total (%) | CAMK2 expression | X2 | P | |
|---|---|---|---|---|---|
|
| |||||
| Low | High | ||||
| Age | |||||
| < 50 | 23 (15) | 11 (47.8) | 12 (52.2) | 0.494 | 0.499 |
| ≥ 50 | 130 (85) | 52 (40) | 78 (60) | ||
| Sex | |||||
| Male | 77 (50.3) | 32 (41.6) | 45 (58.4) | 0.009 | 1.000 |
| Female | 76 (49.7) | 31 (40.8) | 45 (59.2) | ||
| Smoking | |||||
| Never smoker | 90 (58.8) | 35 (38.9) | 55 (61.1) | 0.472 | 0.509 |
| Former or current smoker | 63 (41.2) | 28 (44.4) | 35 (55.6) | ||
| Tumor Size (cm) | |||||
| ≥ 3 | 78 (51) | 30 (38.5) | 48 (61.5) | 0.484 | 0.514 |
| < 3 | 75 (49) | 33 (44) | 42 (56) | ||
| Histological type | |||||
| Acinar predominant | 56 (36.6) | 29 (51.8) | 27 (48.2) | ||
| Lepidic predominant | 51 (33.3) | 24 (47.1) | 27 (52.9) | ||
| Papilary predominant | 17 (11.1) | 6 (35.3) | 11 (64.7) | 12.65 | 0.013* |
| Solid predominant | 17 (11.1) | 3 (17.6) | 14 (82.4) | ||
| Micropapilary predominant | 12 (7.8) | 1 (8.3) | 11 (91.7) | ||
| TNM stage | |||||
| TNMI | 55 (35.9) | 31 (56.4) | 24 (43.6) | ||
| TNMII | 40 (26.1) | 15 (37.5) | 25 (62.5) | 8.937 | 0.030* |
| TNM III | 39 (25.5) | 12 (30.8) | 27 (69.2) | ||
| TNM IV | 19 (12.4) | 5 (26.3) | 14 (73.7) | ||
| Lymphatic Metastasis | |||||
| Present | 66 (43.1) | 19 (28.8) | 47 (71.2) | 7.355 | 0.008* |
| Absent | 87 (56.9) | 44 (50.6) | 43 (49.4) | ||
| Distant Metastasis | |||||
| Present | 49 (32) | 14 (28.6) | 35 (71.4) | 4.729 | 0.035* |
| Absent | 104 (68) | 49 (47.1) | 55 (52.9) | ||
| EGFR | |||||
| Mutation | 56 (36.6) | 17 (30.4) | 39 (69.6) | 4.269 | 0.042* |
| Wild | 97 (63.4) | 46 (47.4) | 51 (52.6) | ||
*
Significantly different.